Akari Therapeutics PLC (AKTX)
1.24
-0.23
(-15.65%)
USD |
NASDAQ |
Nov 21, 16:00
1.28
+0.04
(+3.23%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value: 24.35M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 24.35M |
| November 20, 2024 | 29.10M |
| November 19, 2024 | 31.17M |
| November 18, 2024 | 46.03M |
| November 15, 2024 | 41.70M |
| November 14, 2024 | 44.79M |
| November 13, 2024 | 25.96M |
| November 12, 2024 | 26.69M |
| November 11, 2024 | 26.69M |
| November 08, 2024 | 28.51M |
| November 07, 2024 | 28.27M |
| November 06, 2024 | 26.87M |
| November 05, 2024 | 28.27M |
| November 04, 2024 | 28.26M |
| November 01, 2024 | 32.52M |
| October 31, 2024 | 27.90M |
| October 30, 2024 | 28.02M |
| October 29, 2024 | 29.12M |
| October 28, 2024 | 27.90M |
| October 25, 2024 | 27.47M |
| October 24, 2024 | 26.32M |
| October 23, 2024 | 25.59M |
| October 22, 2024 | 24.66M |
| October 21, 2024 | 24.99M |
| October 18, 2024 | 25.96M |
| Date | Value |
|---|---|
| October 17, 2024 | 25.59M |
| October 16, 2024 | 29.36M |
| October 15, 2024 | 29.73M |
| October 14, 2024 | 31.00M |
| October 11, 2024 | 31.54M |
| October 10, 2024 | 30.82M |
| October 09, 2024 | 34.58M |
| October 08, 2024 | 35.92M |
| October 07, 2024 | 35.61M |
| October 04, 2024 | 35.26M |
| October 03, 2024 | 35.19M |
| October 02, 2024 | 34.94M |
| October 01, 2024 | 35.19M |
| September 30, 2024 | 34.58M |
| September 27, 2024 | 32.53M |
| September 26, 2024 | 33.86M |
| September 25, 2024 | 35.20M |
| September 24, 2024 | 33.01M |
| September 23, 2024 | 35.69M |
| September 20, 2024 | 35.93M |
| September 19, 2024 | 35.20M |
| September 18, 2024 | 34.96M |
| September 17, 2024 | 37.14M |
| September 16, 2024 | 36.54M |
| September 13, 2024 | 36.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.016M
Minimum
Mar 30 2023
135.22M
Maximum
Feb 19 2021
41.91M
Average
41.37M
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 1.221M |
| Cellectis SA | -28.39M |
| Adaptimmune Therapeutics PLC | 26.67M |
| Biodexa Pharmaceuticals PLC | -3.355M |
| NuCana PLC | -11.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.895M |
| Total Expenses (Quarterly) | 1.852M |
| EPS Diluted (Quarterly) | -0.2374 |
| Earnings Yield | -221.9% |